Matthew B Elliott

Summary

Affiliation: Wyeth Research
Country: USA

Publications

  1. ncbi Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques
    Matthew B Elliott
    Wyeth Research, 401 N Middletown Road, Pearl River, NY 10965, USA
    Vaccine 25:7132-44. 2007
  2. ncbi Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein
    Matthew B Elliott
    Department of Immunology, Wyeth Vaccines Research, 401 N. Middletown Rd, Pearl River, NY 10965, USA
    J Virol 78:8446-54. 2004
  3. ncbi Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in the respiratory tracts of human infants following paramyxovirus infection
    Matthew B Elliott
    Wyeth Research, Pearl River, NY 10965, USA
    J Med Virol 79:447-56. 2007
  4. ncbi Recombinant respiratory syncytial viruses lacking the C-terminal third of the attachment (G) protein are immunogenic and attenuated in vivo and in vitro
    Matthew B Elliott
    Wyeth Vaccines Research, 401 N. Middletown Rd, Pearl River, NY 10965, USA
    J Virol 78:5773-83. 2004
  5. ncbi Inhibition of respiratory syncytial virus infection with the CC chemokine RANTES (CCL5)
    Matthew B Elliott
    Department of Immunology Research, Wyeth Vaccines Research, Pearl River, New York 10965, USA
    J Med Virol 73:300-8. 2004

Detail Information

Publications5

  1. ncbi Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques
    Matthew B Elliott
    Wyeth Research, 401 N Middletown Road, Pearl River, NY 10965, USA
    Vaccine 25:7132-44. 2007
    ..The immune responses in mice were also protective against intranasal challenge with RSV. Thus, the replicon-based platform represents a promising new strategy for vaccines against RSV...
  2. ncbi Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein
    Matthew B Elliott
    Department of Immunology, Wyeth Vaccines Research, 401 N. Middletown Rd, Pearl River, NY 10965, USA
    J Virol 78:8446-54. 2004
    ..These findings are important for the development of attenuated RSV vaccines...
  3. ncbi Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in the respiratory tracts of human infants following paramyxovirus infection
    Matthew B Elliott
    Wyeth Research, Pearl River, NY 10965, USA
    J Med Virol 79:447-56. 2007
    ..Taken together, the data suggested that paramyxovirus infection perturbs MMP-9/TIMP-1 homeostasis that in turn may contribute to the severity of respiratory tract disease...
  4. ncbi Recombinant respiratory syncytial viruses lacking the C-terminal third of the attachment (G) protein are immunogenic and attenuated in vivo and in vitro
    Matthew B Elliott
    Wyeth Vaccines Research, 401 N. Middletown Rd, Pearl River, NY 10965, USA
    J Virol 78:5773-83. 2004
    ..Collectively, the data indicate that the rA2cpDeltaG strains are immunogenic, not likely to revert to the less-attenuated phenotype, and thus candidates for further development as vaccines against RSV...
  5. ncbi Inhibition of respiratory syncytial virus infection with the CC chemokine RANTES (CCL5)
    Matthew B Elliott
    Department of Immunology Research, Wyeth Vaccines Research, Pearl River, New York 10965, USA
    J Med Virol 73:300-8. 2004
    ..Flow cytometry further revealed that epithelial cells were positive for CCR3, but not CCR1 or CCR5. Thus, novel mimetics of CCL5 may be useful prophylatic agents to prevent respiratory tract disease caused by RSV...